HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL)

HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL)

In this article results of the multicenter trial are displayed. Data of successful efficacy of trastuzumab treatment in HER2 positive gastric cancer patients has shown.

Saved in:

Bibliographic Details
Main Authors:	H. C. Chung, Y-J. Bang, J. M. Xu, F. Lordick, A. Sawaki, O. Lipatov, M. Lehle, М. Pickl, J. Ruschoff, E. Van Cutsem
Format:	Article
Language:	English
Published:	Bashkir State Medical University 2017-02-01
Series:	Креативная хирургия и онкология
Subjects:	gastric cancer chemotherapy her2 testing trastuzumab
Online Access:	https://www.surgonco.ru/jour/article/view/185
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-term survival after multidisciplinary treatments for HER2-positive advanced gastric cancer with multiple liver and lung metastases
by: Satoshi Yoshioka, et al.
Published: (2023-08-01)

Histopathological Study of Gastric Adenocarcinoma with Special Reference to Expression of HER2/neu and Ki-67 Assessed by Immunohistochemistry
by: Saiqa Nisar, et al.
Published: (2024-10-01)

Hedgehog inhibitors exert anti-proliferation effects and synergistically interact with trastuzumab in HER2-positive gastric cancer models
by: Zixin Yang, et al.
Published: (2025-05-01)

The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers
by: Joseph Edward Haigh, et al.
Published: (2024-09-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

Interobserver variability in her2 immunohistochemistry analysis and its clinical implications with the advent of the HER2-low category
by: Ana Catharina Joaquim, et al.
Published: (2025-08-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
by: Vincenzo Nasca, et al.
Published: (2025-04-01)

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer
by: Xuchen Zhang, et al.
Published: (2025-07-01)

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01)

The influence of H. pylori infection in HER2-positive gastric cancer cell lines: insights from Wnt/β-catenin pathway
by: Valli De Re, et al.
Published: (2025-06-01)

Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?
by: Wiebren Tjalma, et al.
Published: (2025-06-01)

Concordance of HER2-low scoring in breast carcinomas among pathologists
by: Snježana Tomić, et al.
Published: (2025-07-01)

Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
by: Mark Hensley, et al.
Published: (2025-07-01)

Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study
by: Fangchao Zheng, et al.
Published: (2025-05-01)

Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use
by: C. García-Muñoz, et al.
Published: (2014-03-01)

Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study
by: Junxiao Wang, et al.
Published: (2025-07-01)

Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
by: Yisun Jeong, et al.
Published: (2024-12-01)

Trastuzumab Potentiates Antitumor Activity of Thiopyrano[2,3-<i>d</i>]Thiazole Derivative in AGS Gastric Cancer Cells
by: Piotr Roszczenko, et al.
Published: (2024-10-01)

Engineering M13 bacteriophage to display HER2 mimotopes on pVIII for vaccine development
by: Narmin Nazeri, et al.
Published: (2025-07-01)

Prospective Cohort Study of Trastuzumab Biosimilar CT-P6 in HER2-Positive Gastric Cancer: Japanese Real-World Outcomes
by: Hiroya Taniguchi, et al.
Published: (2025-05-01)

Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report
by: Ayaka Isogai, et al.
Published: (2023-06-01)

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01)

Breaking the dichotomy of HER2: highlighting the flaws of simplifying variables
by: Jacob Pozin, et al.
Published: (2025-05-01)

Effect of HER2 Ile655Val polymorphism on the response to trastuzumab treatment in HER2-positive breast cancer patients
by: Zohreh Gheibipour, et al.
Published: (2025-07-01)

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study
by: K. Nakanishi, et al.
Published: (2025-06-01)

HER2-low breast cancer. Diagnostics, treatment and its adverse events
by: Hanna Bartkowiak, et al.
Published: (2024-12-01)

Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer
by: Seema Gulia, et al.
Published: (2016-01-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

HER2-Positive Breast Cancer—Current Treatment Management and New Therapeutic Methods for Brain Metastasis
by: Hanna Miski, et al.
Published: (2025-05-01)

Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report
by: Hiromi Nagata, et al.
Published: (2020-01-01)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
by: Fei Xing, et al.
Published: (2023-01-01)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
by: Scott A Wu, et al.
Published: (2023-09-01)

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01)

Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer
by: Ana Lameirinhas, et al.
Published: (2025-03-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Human Epidermal Growth Factor Receptor 2 [HER‐2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran
by: Samaneh Salarvand, et al.
Published: (2025-08-01)

HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01)

Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy
by: Jinmei Zhou, et al.
Published: (2025-05-01)

Pyrotinib monotherapy for advanced HER2-positive esophageal adenocarcinoma with trastuzumab resistance and chemotherapy intolerance: a case report and literature review
by: Tao Wang, et al.
Published: (2025-03-01)